Product Information
Registration Status: ActiveSIN15218P
LEVOFLOXACIN KABI SOLUTION FOR INFUSION 5MG/ML is approved to be sold in Singapore with effective from 2017-04-20. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN15218P.
This product contains Levofloxacin 5mg/ml in the form of INFUSION, SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by Fresenius Kabi Poland Sp. z.o.o in POLAND.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Indication
For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Mechanism of Action
Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
Pharmacokinetics
- Absorption
- Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
- Distribution
- Metabolism
- Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.
- Elimination
Toxicity
Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
Active Ingredient/Synonyms
(-)-Ofloxacin | (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid | (S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid | (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid | (S)-Ofloxacin | L-Ofloxacin | Levofloxacin anhydrous | Levofloxacine | Levofloxacino | Levofloxacinum | Ofloxacin S-(-)-form | Levofloxacin |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.